FGFR3 and small cell lung carcinoma: Abnormal FGFR3-signaling might have contributed to the rapid progression in this patient despite erlotinib-treatment, with the phenotypic pleural SCLC transformation acting as an additional potent resistance mechanism that contributed to effectively by-passing the TKI-mediated EGFR-blockade.